The Society for Immunotherapy of Cancer's annual meeting, taking place Nov. 8-12, will feature research from Winship investigators that could change how cancer is prevented, diagnosed and treated using immune-based approaches. (Photo: SITC)
The 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), taking place in Boston and online, Nov. 8-12, 2022, will feature research from Winship Cancer Institute of Emory University that could change how cancer is prevented, diagnosed and treated using immune-based approaches.
The research represents some of the latest preclinical and clinical data from Winship-led studies and is relevant to several tumor types, including multiple myeloma, melanoma, and lung, kidney, pancreatic and gynecological cancers.
SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy through its initiatives, education and collaborative endeavors. Its annual meeting is the largest cancer immunotherapy conference in the world and brings together scientists from around the world who are driving innovations in the field. Fellows of SITC’s Academy of Immuno-Oncology include 2022 inductee Rafi Ahmed, PhD, professor of microbiology and immunology in the Emory School of Medicine and co-leader of Winship's Cancer Immunology Research Program.
Meeting highlights include:include podium talks by Winship members Anant Madabhushi, PhD, and Michael Lowe, MD, MA; a session on "Tertiary Lymphoid Structures" co-chaired by Winship member Haydn Kissick, PhD, and featuring original research from the Kissick lab; and oral abstracts from Winship member Brian Olson, PhD, and doctoral students Kelsey Bennion and Anna Cole. Additionally, Winship researchers will present more than a dozen scientific posters throughout the meeting.
Winship-led presentations and sessions at SITC 2022
Tuesday, Nov. 8
- Radiomics, Pathomics, AI for Predicting and Monitoring Treatment Response for Cancer Therapies: Validation on Clinical Trial Datasets
Session 1: Using Artificial Intelligence, Machine Learning, And/Or Predictive Models To Identify Patients Who Will Most Likely Respond To Early Intervention
Anant Madabhushi, PhD
2:05pm, Momentum Ballroom
Thursday, Nov. 10
- Introduction to Radiomics
Session 109: Advances in Imaging Biomarkers, Radiomics, and Artificial Intelligence
Anant Madabhushi, PhD
4:52pm, Room 253ABC - Cellular Composition of TCF1+ CD8 T-cell Immune Neighborhoods in Human Cancers
Session 120: Tertiary Lymphoid Structures
Haydn Kissick, PhD (co-chair, speaker)
6:05pm, Room 210ABC
Poster session, 9:00am - 9:00pm, Poster Hall
- Combination of novel biomarkers of collagen fiber and immune architecture are associated with clinically relevant outcomes in gynecological cancers treated with immunotherapy
Abstract #61
Arpit Aggarwal, PhD candidate - Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab
Abstract #73
Mohammadhadi Khorrami, PhD - Multiplexed Ion Beam Imaging (MIBI) uncovers adaptive immune responses associated with clinical outcomes in oral cavity squamous cell carcinoma treated with neoadjuvant PD-1 inhibitor
Abstract #89
Raghav Padmanabhan - Mitochondrial transcription is required for the enhanced anti-tumor activity of adoptively transferred stem-like memory T cells
Abstract #407
Guillermo Rangel Rivera, BS - Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
Abstract #475
Namrata Patil, PhD - Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma
Abstract #613
Brian Olson, PhD - Stem-like CD8 T-cells residing in antigen presenting immune niches are prognostic for local control in brain metastases and are sustained following radiation therapy
Abstract #1033
Caroline Jansen, PhD - The Role of CD26 in Pancreatic Ductal Adenocarcinoma
Abstract #1457
Maggie Phillips, BS
Friday, Nov. 11
- The Expanding Role of Surgery in Stage IV Melanoma
Session 210: Cancer Surgery in the Age of Immunotherapy
Michael Lowe, MD, MA
4:40pm, Ballroom East - Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma
Session 210: Cancer Surgery in the Age of Immunotherapy
Brian Olson, PhD
5:20pm, Ballroom East - FcγRIIB expressed on CD8 T cells limits responsiveness to PD-1 checkpoint inhibition in cancer
Session 215: Poster Symposium
Kelsey Bennion, BS
5:40pm, Ballroom East - Adoptively transferred Th17 cells cooperate with host B cells to mediate robust immunity to tumors
Session 215: Poster Symposium
Anna Cole, BA
6:00pm, Ballroom East
Poster session, 9:00am - 8:30pm, Poster Hall
- B and Myeloid Cell Populations Dominate in the Metastasis Compared to Primary Tumors of Patients with Pancreatic Cancer
Abstract #134
Emily Greene, MS - Adoptively transferred Th17 cells cooperate with host B cells to mediate robust immunity to tumors
Abstract #212
Anna Cole, BA - Engineering optimal CAR T cells to overcome pancreatic tumors with secreted antagonistic peptides
Abstract #310
Heather Lin, BS - Increased activity of the ATX/LPA axis diminishes CD8+ T cell cytotoxicity via LPAR5 signaling, driving immune checkpoint blockade resistance in non-small cell lung cancer
Abstract #450
Jessica Konen, PhD - Impact of immunotherapy time-of-day infusion on overall survival in patients with metastatic renal cell carcinoma
Abstract #848
Jimmy Patel - Regulation of neoantigen-specific T-cell infiltration and spatial tumor-immune architecture of myeloma and its premalignant precursors
Abstract #1458
Nancy Villa, PhD